The Partnership Seeks to Develop
Cannabis-Based Products for the Treatment of Human Diseases,
Beginning with Colon Cancer
CORONA, CA, Nov. 8, 2019 /PRNewswire/ - Ikänik Farms, Inc.
(the "Company") is pleased to announce that Ikänik International,
Inc. ("Ikänik International"), represented by its medical division
in Colombia, Pideka SAS has signed
a two-year collaborative R&D agreement with Corporation for
Biological Research ("CIB"), a non-profit Colombian scientific
research corporation center, to develop cannabis-based products for
the treatment of human diseases.
"CIB has a national reputation as a center of excellence for
biological research," said Brian
Baca, CEO of Ikänik Farms. "We look forward to
working with some of Colombia's
leading academics, including clinical and technological
specialists, to advance the development of cannabis-based medical
treatments."
The initial objective will be focused on researching and
developing cannabis-based products to help prevent and slow the
growth of colon cancer cells with treatment of cannabinoids,
through nanotechnology. Ikänik Farms will be responsible for
producing cannabis plant material for CIB, collaborating on the
research and by conducting tests on the derivatives of the cannabis
plant material in order to evaluate the efficacy in the treatment
of colon cancer.
Pending the successful completion of the testing phase, Ikänik
Farms will work with CIB to apply formulation technologies to the
derivatives (based upon technology developed by the Corporation for
Biological Research) to create a colon cancer treatment model
through pre-clinical and clinical studies.
"Ikänik Farms and CIB are collaborating on research
aimed to develop cannabis-based products for the pharmaceutical
market to treat diseases in humans, while increasing the scientific
understanding of the cannabis plant and its use in future
applications" said Borja Sanz de
Madrid, President of Ikänik international.
About CIB
The Corporation for Biological Research, "CIB", is a scientific
research institution classified by Colombian sciences as a research
center of excellence specializing in health science biodiversity,
agricultural and environmental biotechnology. Their work is based
on research, clinical and technological developments in the area of
biological sciences collaborating with national and international
partners. CIB seeks to build relationships with productive sectors
through innovation and technology and currently participate in the
training of researchers, the provision of specialized services and
academic dissemination.
CIB is comprised of five participating universities; Universidad
Pontificia Bolivariana (UPB), Universidad Nacional de Colombia sede Medellin (UN), Institucion Universitaria
Colegio Mayor de Antioquia, Universidad de Santander (UDES) and
Universidad de Antioquia. For further information regarding
CIB, please refer to their website:
http://cib.org.co/quienes-somos/
About Ikänik Farms
Ikänik Farms is creating a dynamic portfolio of cannabis
lifestyle brands, deep rooted in action sports and entertainment
and unified with passion. Ikänik Farm's leadership brings decades
of expertise in R&D, cultivation, retail, branding, and finance
with the ambition to build the nation's most iconic vertically
integrated "seed-to-sale", "MNO" Multi-National Operator. Ikänik
Farm's operations are currently located in California and
Colombia.
About Pideka SAS
Pideka is a medicinal cannabis company authorized by the
Colombian government to cultivate, produce, manufacture and export
cannabis derivatives, extracts and seeds for medical and scientific
purposes. In addition to being Colombia's first licensed indoor cannabis
producer, Pideka was responsible for opening Colombia's first legal medicinal cannabis
dispensary in 2014.
Forward Looking Statements
This news release includes "forward-looking information" and
"forward-looking statements" within the meaning of Canadian
securities laws and United States securities laws
(together, "forward-looking information). All information, other
than statements of historical facts, included in this news release
that address activities, events or developments that the Company
expects or anticipates will or may occur in the future is
forward-looking information. When used in this news release, words
such as "will", "could", "plan", "estimate", "expect", "intend",
"may", "potential", "believe", "should", and similar expressions,
are forward-looking information, including, but not limited to, the
success of the testing phase with respect to cannabis-based
medicinal treatment.
Although the Company has attempted to identify important factors
that could cause actual results, performance or achievements to
differ materially from those contained in the forward-looking
information, there can be other factors that cause results,
performance or achievements not to be as anticipated, estimated or
intended, including, but not limited to: the inability to obtain
the necessary regulatory and stock exchange approvals, changes in
laws, a change in management, the inability to obtain additional
financing, increased competition, hindering market growth and state
adoption due to inconsistent public opinion and perception of the
medical-use and adult-use marijuana industry and regulatory or
political change.
There can be no assurance that such information will prove to be
accurate or that management's expectations or estimates of future
developments, circumstances or results will materialize. As a
result of these risks and uncertainties, the results or events
predicted in the forward-looking information may differ materially
from actual results or events.
Accordingly, readers should not place undue reliance on
forward-looking information. The forward-looking information in
this news release is made as of the date of this release. The
Company disclaims any intention or obligation to update or revise
such information, except as required by applicable law, and the
Company does not assume any liability for disclosure relating to
any other company mentioned herein.
On behalf of the Board of Directors of Ikänik Farms, Inc.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ikanik-farms-signs-collaborative-rd-agreement-with-corporation-for-biological-research-cib-a-colombian-scientific-research-corporation-300954746.html
SOURCE Ikänik Farms Inc.